Pharmaceutical Industry Articles & Reports

Learn pharmaceutical cleaning validation principles, including Health-Based Exposure Limits (HBEL/PDE), MACO calculations, and lifecycle validation software.

Analyze Annual Product Quality Review (APQR) requirements comparing FDA 21 CFR 211.180(e) and EU GMP Chapter 1. Explore data trending and automation tools.

Review pharma product complaint management regulations, including FDA 21 CFR 211.198 and EU GVP. Analyze CAPA linkage, reporting requirements, and eQMS tools.

Review the FDA approval of Datroway (datopotamab deruxtecan) for first-line metastatic TNBC. Analyze TROPION-Breast02 efficacy, survival, and safety data.

Analyze the June 2026 FDA draft guidance on cell and gene therapies. Understand how reusing platform knowledge streamlines CMC submissions and development.

Examine the architecture and adoption of Salesforce Agentforce Life Sciences. Learn how agentic CRM, headless design, and AI impact pharma commercial teams.

Analyze Sanofi's Concierge for Field, an agentic AI tool built on Snowflake Cortex and Elementum AI to automate pharma sales prep and update operating models.

Examine ASCO 2026 HARMONi-6 trial data for ivonescimab in 1L squamous NSCLC. Understand OS outcomes, PD-1xVEGF efficacy, and Summit Therapeutics US strategy.

Review the FDA approval of tradipitant for motion sickness. Explore the pharmacology of this NK-1 receptor antagonist and its 505(b)(2) regulatory pathway.

This analysis explains the May 2026 FDA draft guidance on nonclinical safety studies for oncology biologics, single-species toxicology, and WoE approaches.

Explore the clinical data and 505(b)(2) FDA regulatory pathway for CTx-1301 (dexmethylphenidate), a novel once-daily stimulant candidate for ADHD treatment.

Analyze the HelioLiver AI blood test for early liver cancer detection. Examine its clinical efficacy, CRO commercialization, and MCED adoption strategies.

Analyze Bristol Myers Squibb's deployment of Anthropic Claude to 30,000 employees. Examine agentic AI enterprise strategies and pharma change management.

Analyze the integration of agentic AI systems in pharmaceutical R&D, examining Incyte's adoption of the Kosmos AI Scientist for automated drug discovery.

Analyze the FDA's three-month PDUFA delay for subcutaneous Sarclisa. Examine its on-body injector technology, clinical data, and anti-CD38 competitors.

Examine the $10.5B Pfizer-Innovent collaboration. This analysis covers their 12-drug ADC oncology portfolio and the China cross-border licensing playbook.

Analyze the May 2026 FDA approval of Afrezza inhaled insulin for pediatric diabetes. Review INHALE-1 clinical trial data, T1D/T2D options, and market impacts.

Review the May 2026 FDA approval of Decnupaz (pivekimab sunirine), the first CD123-targeted ADC for BPDCN. Explores clinical efficacy and launch strategies.

Analyze the role of Perceptic's AI operating system in pharmaceutical R&D. Learn how unifying end-to-end data pipelines impacts drug discovery processes.

Examine the FDA's August 2026 PDUFA extension for Leqembi IQLIK. Understand the subcutaneous lecanemab clinical data, treatment costs, and infusion capacity.

Examine Eli Lilly's $3.8B acquisition of three biotechs to build an infectious disease vaccine pipeline targeting shingles, EBV, and resistant bacteria.

Learn how AI pathology and deep-learning TME quantification link to postoperative ctDNA status and clinical outcomes in stage III colon cancer patients.

Analyze Google Science Skills and Gemini for Science. Understand how AlphaFold and AlphaGenome integrations impact pharma informatics and vendor evaluation.

A comprehensive guide to the ICH Q14 analytical procedure development guideline. Review the enhanced QbD approach, lifecycle management, and ATP integration.